Search results
Results from the WOW.Com Content Network
It is a suitable pharmacological agent for the reduction of renal disease progression in patients with type 2 diabetes, hypertension, and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours). [14]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The subject expert committee of CDSCO has recommended the grant of permission for manufacturing and marketing of Desidustat 25 mg and 50 mg tablets in India, based on some conditions related to package insert, phase 4 protocols, prescription details, and GCP. [3] Clinical trials on desidustat have been done in India and Australia. [4]
Amlodipine/olmesartan, sold under the brand name Azor, among others is a fixed-dose combination medication used to treat high blood pressure. [5] It contains amlodipine, as the besilate, a dihydropyridine calcium channel blocker, and olmesartan medoxomil, an angiotensin II receptor blocker.
MXL is a 24-hour release formula designed to be taken once daily. It is available in doses between 30 mg and 200 mg in 30 mg intervals (equating to between 1.25 mg/hour and 8.33 mg/hour). MST Continus is a 12-hour release formula, therefore it is given 2 times per day.
Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V 2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).
[37] [38] Participants were randomized to therapy with upadacitinib at 3, 6, 12, 24 mg twice daily or 24 mg once daily for 16 weeks or placebo, followed by blinded extension therapy for 36 weeks. The co-primary endpoints were the proportion of participants who achieved clinical remission (soft stool frequency or daily abdominal pain score) at ...
Elon Musk v. RFK Jr.’s stance on Ozempic. In November, the Biden administration announced plans to provide coverage for costly anti-obesity medications, including Wegovy and Zepbound, for ...